Literature DB >> 3061449

Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.

L Ficker1, G Vafidis, A While, P Leaver.   

Abstract

In a prospective randomised trial of argon laser photocoagulation in the management of central serous retinopathy, long-term follow-up (6.4 to 12.1 years) revealed no evidence that treatment significantly influenced the visual outcome as measured by the Snellen chart and by the Farnsworth-Munsell 100-hue test. Treatment did not reduce either the recurrence rate or the prevalence of chronic disease. Complications of treatment were uncommon. The justification for argon laser photocoagulation appears to be limited to the hastening of symptomatic relief by earlier resolution of serous detachment.

Entities:  

Mesh:

Year:  1988        PMID: 3061449      PMCID: PMC1041600          DOI: 10.1136/bjo.72.11.829

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  MACULAR DISEASES: CLINICAL MANIFESTATIONS.

Authors:  A E MAUMENEE
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1965 Jul-Aug

2.  Treatment of persistent central serous retinopathy.

Authors:  R R Peabody; H C Zweng; H L Little
Journal:  Arch Ophthalmol       Date:  1968-02

3.  Long-term follow-up of central serous retinopathy.

Authors:  M Nanjiani
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09

4.  Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy.

Authors:  D M Robertson; D Ilstrup
Journal:  Am J Ophthalmol       Date:  1983-04       Impact factor: 5.258

5.  Direct and indirect laser photocoagulation of central serous choroidopathy.

Authors:  R C Watzke; T C Burton; R F Woolson
Journal:  Am J Ophthalmol       Date:  1979-11       Impact factor: 5.258

6.  Argon laser photocoagulation in the treatment of central serous retinopathy.

Authors:  P Leaver; C Williams
Journal:  Br J Ophthalmol       Date:  1979-10       Impact factor: 4.638

7.  Retinal dysfunction in central serous retinopathy.

Authors:  E L Chuang; D M Sharp; F W Fitzke; C M Kemp; A L Holden; A C Bird
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

8.  Long-term follow-up of central serous chorioretinopathy.

Authors:  C M Gilbert; S L Owens; P D Smith; S L Fine
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

9.  Retinal pigment epithelium decompensation. I. Clinical features and natural course.

Authors:  A E Jalkh; N Jabbour; M P Avila; C L Trempe; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

10.  Cyclic AMP modulation of ion transport across frog retinal pigment epithelium. Measurements in the short-circuit state.

Authors:  S Miller; D Farber
Journal:  J Gen Physiol       Date:  1984-06       Impact factor: 4.086

View more
  57 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

3.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

Review 4.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

5.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

6.  Surgical management of bilateral exudative retinal detachment associated with central serous chorioretinopathy.

Authors:  Ji Eun Kang; Hyun Jin Kim; Hee Don Boo; Ha Kyoung Kim; Jeong Hee Lee
Journal:  Korean J Ophthalmol       Date:  2006-06

7.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

8.  Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Authors:  Xing-Wang Chen; Fang-Yuan Han; Gang Su; Le Pan; Shan-Jun Cai
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Authors:  S H Lim; W Chang; M Sagong
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.